Company news

ImmuneOnco Biopharma won the project supported by Science and Technology Commission of Shanghai Municipality

2018-6-29 0:00:00Click:72

 On June 29, 2018, ImmuneOnco Biopharma Co., Ltd., an emerging biotech company fully focusing on discovery and development of tumor immunotherapy, announced that, one of its research projects won the supportion by Shanghai science and technology achievements transformation and industrialization project; the project No.: 18431903400. The project is a preclinical study of a anti-tumor bi-functional antibodies.

 “The bi-functional protein simultaneously targeting CD20/CD47 is one of many exciting programs in our preclinical development portfolio," said Dr. Wenzhi Tian, Chairman and Chief Executive Officer of ImmuneOnco. "

 Binding to CD20 on the surface of lymphoma cell membrane can kill tumor cells through ADCC and CDC pathway; Binding to CD47 makes tumor cell expose to the immune attack activated by the same protein blocking the SIRPa signals. In preclinical studies, the combined inhibition of CD20 and SIRPa has resulted in significant anti-tumor activity in a variety of xenograft models.

 Patent application number in China: 201710151979.6; the title: new recombinant bifunctional fusion protein, its preparation method and application; the inventor: ImmuneOnco Biopharma Co., Ltd.